|Harbor Diversified, Inc.|
9191 Towne Centre Drive
United States - Map
Harbor Diversified, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of products for the treatment of diseases related to aging. The company primarily focuses on the development of a series of steroid hormone analogs that are derived from the human adrenal metabolome. Its development-stage product candidates that have completed Phase I/IIa clinical trials include Apoptone (HE3235) for use in patients with late-stage prostate cancer; and Triolex (HE3286) used in obese type 2 diabetes mellitus patients. The company was formerly known as Harbor BioSciences, Inc. and changed its name to Harbor Diversified, Inc. in February 2012. Harbor Diversified, Inc. was founded in 1992 and is headquartered in San Diego, California.
|Dr. James M. Frincke Ph.D.,
Chief Exec. Officer, Pres and Director
|Mr. Robert W. Weber ,
Chief Financial Officer, Chief Accounting Officer, VP of Operations, Controller and Sec.
|Dr. Christopher L. Reading Ph.D.,
Chief Scientific Officer
|Mr. Scott A. Rieger ,
VP of Corp. Communications
|Mr. Robert L. Marsella ,
Sr. VP of Bus. Devel. and Marketing
|Amounts are as of Dec 31, 2011 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|